ÂÜÀòÂÒÂ×

Dmitri Lissin currently serves as Chief Medical Officer and Senior Vice President, Clinical Development and Medical Affairs of Scilex/Semnur Pharmaceuticals (2015 – present). Prior to Semnur, from 2011-2015, Dmitri was Vice President of Clinical Development at Xenoport, responsible for conduct of multiple clinical research programs in neurology and dermatology. From 2006-2011 Dmitri directed a clinical research team and served as member of the Executive Committee at DURECT Corporation, designing and executing clinical trials in chronic nociceptive, neuropathic, and acute post-operative pain, which led to successful licensing deals and NDA filings. From 1998-2006 Dmitri managed various clinical R&D programs at Titan Pharmaceuticals, Aerogen, and Synarc. Dr. Lissin has a broad expertise with proprietary drug-delivery technologies applied to therapeutic products spanning numerous clinical areas including pain and neurological disorders. Most of his experience involves clinical development of novel oral, transdermal, implantable, and injectable formulations containing existing active pharmaceutical ingredients, using 505(b)(2) drug approval pathway. He has participated in many Pre-IND, End of Phase 1, End of Phase 2, and Pre-NDA meetings, negotiating clinical development programs with the FDA Division of Anesthesia, Analgesia, and Addiction Products (DAAAP), Division of Neurology Products, and Division of Dermatology and Dental Products. He received his post-doctoral training at the University of California San Francisco, and his medical degree through an exchange program between Russian National Medical University and Harvard Medical School.